Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 301 to 315 of 663 results for diabetes

  1. Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)

    Summary of the evidence on antimicrobial prescribing: delafloxacin

    Evidence summary
    Published
    5 January 2021

  2. Awareness of risk among black, Asian and other minority ethnic groups: Are black, Asian and other minority ethnic groups aware that they are at the same risk of type 2 diabetes and mortality at a lower BMI, compared with the white population?

    other minority ethnic groups aware that they are at the same risk of type 2 diabetes and mortality at a lower BMI, compared with the...

    Research recommendation
    Published
    30 September 2022

  3. Drug-eluting stents for treating coronary artery disease: late-stage assessment (HTG747)

    Late-stage assessment (LSA) guidance on drug-eluting stents for treating coronary artery disease.

    HealthTech guidance
    Published
    6 May 2025
    View recommendations

    Sections for HTG747

  4. Single cut-off points: What are the risks and benefits of developing single-figure cut-off points on BMI and waist-to-height ratio for black, Asian and other minority ethnic groups to help prevent diabetes and other conditions?

    ratio for black, Asian and other minority ethnic groups to help prevent diabetes and other conditions? Any explanatory notes(if...

    Research recommendation
    Published
    30 September 2022

  5. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

    Technology appraisal guidance
    Last updated
    2 July 2021
    View recommendations

    Sections for TA256

  6. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)

    Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.

    Technology appraisal guidance
    Published
    24 July 2024
    View recommendations

    Sections for TA988

  7. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds (MIB208)

    NICE has developed a medtech innovation briefing (MIB) on NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds .

    Medtech innovation briefing
    Published
    17 March 2020

  8. Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers (HTG677)

    Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers.

    HealthTech guidance
    Published
    24 May 2023
    View recommendations

    Sections for HTG677

  9. Identification and monitoring:- What are the demographic characteristics and rates of progression to type 2 diabetes among people with a high risk score but normal blood glucose levels (fasting plasma glucose of less than 5.5 mmol/l or HbA1c of less than 42 mmol/mol)? How does this compare with people who have both a high risk score and blood glucose levels that indicate impaired glucose regulation (fasting plasma glucose 5.5–6.9 mmol/l or HbA1c 42–47 mmol/mol (6.0–6.4%)?

    are the demographic characteristics and rates of progression to type 2 diabetes among people with a high risk score but normal blood...

    Research recommendation
    Published
    9 June 2015

  10. Identification and monitoring:- Which combination of risk-assessment tools and blood tests (HbA1c or fasting plasma glucose [FPG]) are most cost effective and effective at identifying and assessing the risk of type 2 diabetes among populations at high risk? In addition, how frequently should testing take place to be efficient? How does effectiveness and cost effectiveness vary for different black and minority ethnic groups, for example, African-Caribbean and black African; people aged 18–40, people aged 75 and over, and for high-risk vulnerable adults?

    effective and effective at identifying and assessing the risk of type 2 diabetes among populations at high risk? In addition, how...

    Research recommendation
    Published
    9 June 2015

  11. Diabetes - buccal insulin [ID311]

    Discontinued Reference number: GID-TAG244

    Technology appraisal guidance
    Discontinued

  12. Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing (HTG479)

    Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture.

    HealthTech guidance
    Published
    31 July 2018
    View recommendations

    Sections for HTG479

  13. Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing (HTG480)

    Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture.

    HealthTech guidance
    Published
    31 July 2018
    View recommendations

    Sections for HTG480

  14. Human and animal bites: antimicrobial prescribing (NG184)

    This guideline sets out an antimicrobial prescribing strategy for human and animal bites (excluding insect bites) in adults, young people and children aged 72 hours and over. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    4 November 2020
    View recommendations

    Sections for NG184

  15. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

    Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

    Technology appraisal guidance
    Last updated
    2 July 2021
    View recommendations

    Sections for TA355